| Identification | Back Directory | [Name]
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one hydrate | [CAS]
851220-85-4 | [Synonyms]
Aripiprazole monohydrate
Aripiprazole monohydrate (OPC14597)
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one hydrate | [EINECS(EC#)]
685-520-1 | [Molecular Formula]
C23H29Cl2N3O3 | [MDL Number]
MFCD30489099 | [MOL File]
851220-85-4.mol | [Molecular Weight]
466.4 |
| Hazard Information | Back Directory | [Uses]
Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19[1][2][3][4]. | [in vivo]
Aripiprazole monohydrate (0-3 mg/kg, IP, daily) shows some anxiolytic properties[4]. | Animal Model: | WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixture of tiletamine/zolazepam)[4] | | Dosage: | 0, 0.3, 1, 3 mg/kg | | Administration: | IP, 1 mL/kg, every day at 5 p.m. until the end of the experiments | | Result: | Showed some anxiolytic properties with the 1 mg/kg dose being the most active. |
| [IC 50]
5-HT1A Receptor; 5-HT2A Receptor; 5-HT2B Receptor; 5-HT2C Receptor; D2 Receptor; D3 Receptor; D4 Receptor | [References]
[1] Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9. DOI:10.1124/jpet.102.033175
[2] Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36. DOI:10.1111/j.1527-3458.2004.tb00030.x
[3] Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701. DOI:10.3389/fphar.2021.646701
[4] Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9. DOI:10.1016/j.neuropharm.2012.06.039 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|